首页> 外文期刊>International journal of antimicrobial agents >Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis
【24h】

Efficacy of repeated cycles of combination therapy for the eradication of infecting organisms in chronic bacterial prostatitis

机译:反复联合疗法在慢性细菌性前列腺炎中根除感染性微生物的功效

获取原文
获取原文并翻译 | 示例
           

摘要

A total of 137 patients with a diagnosis of chronic bacterial prostatitis (CBP) were subjected to combination pharmacological therapy with antibacterial agents (ciprofioxacin/azithromycin), alpha-blockers (alfuzosin) and Serenoa repens extracts. Of those, 88 patients (64.2%) showed microbiological eradication at the completion of a 6-week cycle of therapy. Of the remaining 49 patients showing persistence of the causative organism(s) or reinfection at the end of treatment, 36 completed a second cycle of combination therapy for 6 weeks: 27 patients (75%) showed eradication of the causative organism, whereas in nine cases persistence or reinfection was observed. The cumulative eradication rate of the present study - calculated on a total of 137 enrolled patients - is 83.9%. Clinical examination showed a marked improvement of signs and symptoms linked to prostatitis. Remarkably, combination therapy could attenuate CBP symptoms prior to microbiological eradication, thus rapidly decreasing the impact of the disease on the quality of life of patients. Clinical remission was extended throughout a follow-up period of 30 months for 94% of patients, whereas seven patients showed relapse of the disease. In summary, our results indicate that about 20% of patients enrolled in this study, who were refractory to a protocol of 6-week combination therapy, could be 'rescued' by a second cycle of treatment. Clinical follow-up data show that combination therapy could ensure extended relief from CBP symptoms, and a general improvement in quality of life. (C) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
机译:总共137例诊断为慢性细菌性前列腺炎(CBP)的患者接受了抗菌药物(环丙沙星/阿奇霉素),α受体阻滞剂(阿夫唑嗪)和白蜡油提取物的联合药理治疗。在这些患者中,有88名患者(64.2%)在为期6周的治疗周期结束时显示出微生物根除。在其余49位在治疗结束时表现出病原性生物持续存在或再感染的患者中,有36名完成了第二轮联合治疗,持续了6周:27名患者(75%)表现出根除病原性生物,而在9名中观察到持续性或再感染。本研究的累积根除率-以总共137名入选患者计算-为83.9%。临床检查显示与前列腺炎有关的体征和症状明显改善。值得注意的是,联合治疗可以在消灭微生物之前减轻CBP症状,从而迅速降低疾病对患者生活质量的影响。 94%的患者在30个月的随访期内临床缓解得以延长,而7例患者表明该病已复发。总而言之,我们的结果表明,参加本研究的大约20%的患者对6周联合疗法无效,可以通过第二个疗程“救助”。临床随访数据表明,联合治疗可确保长期缓解CBP症状,并改善生活质量。 (C)2007年Elsevier B.V.和国际化学疗法学会。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号